|
Novartis and Malaria No More provide two million antimalarial treatments to children in Zambia
|
07 April 2014 |
|
Novartis announces US FDA approval of Xolair® for chronic idiopathic urticaria
|
23 March 2014 |
|
Novartis extends leadership in clinical trial data transparency
|
26 February 2014 |
|
Novartis expands cancer immunotherapy research program with acquisition of CoStim
|
17 February 2014 |
|
Novartis recognized among world's most sustainable companies in Corporate Knights Global 100
|
28 January 2014 |
|
Novartis Africa Day highlights company's efforts to expand access to healthcare
|
06 December 2013 |
|
Novartis Foundation launches new leprosy strategy at symposium on disease elimination
|
29 November 2013 |
|
Novartis highlights growth prospects driven by significant R&D pipeline progress and the expected increase in blockbuster treatments
|
25 November 2013 |
|
Novartis announces positive clinical trial results for novel H7N9 vaccine
|
14 November 2013 |
|
Novartis delivers strong sales performance in third quarter
|
22 October 2013 |